AbCellera Biologics (ABCL) saw a 16% decline in its stock price during the week ending May 9th, primarily due to disappointing Q1 earnings and concerns about its revenue trajectory. The company reported $4.24 million in revenue, marking a 57% drop compared to the same quarter in 2024. Additionally, its net loss widened to $45.6 million, further unsettling investors.
Another factor contributing to the decline was AbCellera’s strategic shift toward internal drug development, which led to increased research and development expenses. While this move signals long-term ambitions, investors reacted cautiously to the near-term financial strain.
Additional reading: What Are the Benefits of Ai-Focused Drug Discovery and Development?
